Sensorion to Take part within the LifeSci Companions 2nd Annual Genetic Medicines Symposium on June 29, 2022

Home science Genetics Sensorion to Take part within the LifeSci Companions 2nd Annual Genetic Medicines Symposium on June 29, 2022
Sensorion to Take part within the LifeSci Companions 2nd Annual Genetic Medicines Symposium on June 29, 2022
Sensorion to Take part within the LifeSci Companions 2nd Annual Genetic Medicines Symposium on June 29, 2022

Montpellier, France, June 24, 2022– (BUSINESS WIRE) – Regulatory information:

Sensors (FR0012596468 – ALSEN) (Paris:ALSEN) A number one clinical-stage biotechnology firm that focuses on creating novel therapies for the restoration, therapy, and prevention of listening to loss issues, is happy to announce the participation of Nawal Ozern, CEO of LifeSci Companions 2.second abbreviation The Annual Symposium on Genetic Medicines takes place roughly 28-29 June 2022.

CEO Nawal Ozren will share a chat with Jeff Goodenburg as a part of LifeSci Companions 2second abbreviation Annual Symposium on Genetic Medicines, on June 29, 2022. To attend the dialogue, please register right here. A replay of the reside chat might be obtainable shortly after the presentation ends on the identical hyperlink.

Date: Wednesday 29 June 2022
subsequent to the hearth chat: 8.30 a.m. – 9 a.m. EST (2.30 p.m. – 3 p.m. CST)
OccasionLifeSci 2 . Companionssecond abbreviation Annual Symposium on Genetic Medicines

About Sensor

Sensorion is a number one clinical-stage biotechnology firm that focuses on creating new therapies to revive, deal with and forestall listening to loss issues, a big unmet international medical want.

Sensorion has constructed a novel analysis and growth know-how platform to develop its understanding of the pathophysiology and pathogenesis of the interior ear, enabling it to pick out the most effective targets and strategies for drug candidates. Her portfolio combines small molecule applications with a preclinical portfolio of interior ear genetic therapies.

Its medical part portfolio consists of one Part II product: SENS-401 (Arazasetron) advancing in a deliberate Part II medical examine of the idea of SENS-401 in cisplatin-induced ototoxicity (CIO) and with associate Cochlear Restricted, a examine of SENS-401 in Sufferers scheduled for cochlear implantation.

Sensorion has entered right into a broad strategic collaboration with the Pasteur Institute specializing in the genetics of audiology. It incorporates two gene remedy applications geared toward correcting single-gene genetic types of deafness together with deafness attributable to a mutation within the gene coding for Otoferlin, and listening to loss related to a mutation within the GJB2 gene to deal with necessary listening to loss segments in adults and kids. The corporate can also be working to determine biomarkers to enhance the analysis of those underserved illnesses.

www.sensorion.com

a poster: sensor
inside: FR0012596468
mnemonic: ALSEEN

disclaimer

This press launch incorporates sure forward-looking statements relating to Sensorion and its enterprise. These forward-looking statements are based mostly on assumptions that Sensorion considers cheap. Nevertheless, there could be no assure that these forward-looking statements might be verified, that are topic to quite a few dangers, together with these set forth within the Full 12 months 2021 Monetary Report revealed on April 28, 2022 obtainable on our web site and to creating financial situations. and the monetary markets and markets through which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers that aren’t but recognized to Sensorion or not presently thought of by Sensorion. The prevalence of all or a part of these dangers might trigger Sensorion’s precise outcomes, monetary situations, efficiency or achievements to be materially completely different from such forward-looking statements. This press launch and the data it incorporates don’t represent a proposal to promote or subscribe or a solicitation of a proposal to purchase or subscribe for the shares of Sensorion in any nation. Relaying this press launch in some nations might represent a violation of native legal guidelines and laws. Any recipient of this press launch should inform themselves of and adjust to any such native restrictions.

View the supply model on businesswire.com: https://www.businesswire.com/news/home/20220623005695/ar/

Contacts

Investor Relations
Catherine Levo
Head of Investor Relations and Communication
+33 6 72 18 00 22
[email protected]

Worldwide Media Relations
Strategic Communications Council
Mary Jane Elliott / Jessica Hodgson
+44 7739 788014
+44 7561 424788
[email protected]

Leave a Reply

Your email address will not be published.